Neumifil delivers statistically significant reductions in influenza symptomatic infection rate, symptom severity and viral loadStrategy to advance clinical development of Neumifil to be based on these positive data and pre-clinical data package demonstrating Neumifil’s activity against a broad range of viruses St Andrews, UK – 23nd May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), presented positive results from its Phase 2, proof-of-concept, Controlled Human Infection Model (CHIM) study in which healthy volunteers were challenged with influenza virus following administration of Neumifil.

Neumifil在统计学上显着降低了流感症状感染率，症状严重程度和病毒载量。基于这些阳性数据和临床前数据包，证明了Neumifil对多种病毒的活性，英国圣安德鲁斯-2024年5月23日-Pneumagen是一家临床阶段的生物技术公司，开发了Neumifil（HEX17），一种用于预防和治疗病毒性呼吸道感染（RTI）的广谱抗病毒鼻内药物，在其第2阶段，概念验证，受控人类感染模型（CHIM）研究中，健康志愿者在服用Neumifil后受到流感病毒的挑战。

These data were featured during an oral presentation* at the American Thoracic Society (ATS) in San Diego on 21st May. The presentation, entitled “HEX17, a Novel Broad-spectrum Antiviral Intranasal Drug, Demonstrates Efficacy Against Influenza in a Controlled Human Infection Model Conducted in Healthy Adults,” was delivered by Dr Geoff Kitson, Chief Medical Officer of Pneumagen.

这些数据在5月21日于圣地亚哥举行的美国胸科学会（ATS）的一次口头报告*中得到了介绍。该报告题为“HEX17，一种新型广谱抗病毒鼻内药物，在健康成年人中进行的受控人类感染模型中显示出抗流感的功效”，由Pneumagen首席医疗官Geoff Kitson博士发表。

“We are very pleased to present detailed data from our Phase 2 Clinical trial of Neumifil,” said Douglas Thomson, Chief Executive Officer of Pneumagen. “Based on these promising proof-of-concept results presented at ATS, that reinforce the clinically significant reduction in both the incidence and severity of symptomatic influenza infection, we now look forward to advancing Neumifil into further clinical studies where its broad spectrum of activity offers significant potential.

Pneumagen首席执行官道格拉斯·汤姆森（DouglasThomson）表示：“我们很高兴提供Neumifil 2期临床试验的详细数据。“基于ATS上提出的这些有希望的概念验证结果，加强了症状性流感感染发病率和严重程度的临床显着降低，我们现在期待着将Neumifil推进进一步的临床研究，其广泛的活性提供了巨大的潜力。

These trials are expected to include the evaluation of Neumifil’s ability to reduce the incidence of exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD), wh.

预计这些试验将包括评估Neumifil降低慢性阻塞性肺疾病（COPD）患者急性加重发生率的能力。